The UroGist

UroGen® Pharma
  • 5.0 (5)
  • HEALTH & FITNESS

The UroGist is a podcast series from UroGen Pharma, that takes an informative and engaging look at the latest in urologic oncology through enlightening and interesting conversations with leading urologists and other stakeholders. Hosted by Dr. Michael Louie, the SVP of Medical Affairs and Clinical Development at UroGen. The UroGist seeks to provide a more contextualized understanding of advances in the field that are reshaping the treatment landscape for urologic cancers.

Episodes

  1. JAN 10

    Navigating Low-Grade Upper Tract Urothelial Cancer: A Patient’s Journey

    In this episode of The UroGist, host Dr. Mike Louie of UroGen is joined by Dr. Pascal de Caprariis, a patient with low-grade upper tract urothelial cancer (LG-UTUC) and an infectious disease specialist. Dr. de Caprariis shares his unique perspective as both a physician and a person living with LG-UTUC, discussing his diagnosis, treatment journey, and offering advice to others facing similar challenges. Documents to link in episode description:  JELMYTO Full Prescribing Information, Instructions for Pharmacy, Instructions for Administration, and Patient Package Insert  JELMYTO Important Safety Information The OLYMPUS Study JELMYTO Instructions for Administration  Antegrade Administration of JELMYTO  The Journal of Urology – Surena F. Matin, Phillip M. Pierorazio, Nir Kleinmann, John L. Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott G. Hubosky, Marcelino Rivera, Michael O’Donnell, Marcus Quek, Jay D. Raman, John J. Knoedler, Douglas Scherr, Christopher Weight, Alon Weizer, Michael Woods, Hristos Kaimakliotis, Angela B. Smith, Jennifer Linehan, Jonathan Coleman, Mitchell R. Humphreys, Raymond Pak, David Lifshitz, Michael Verni, Ifat Klein, Marina Konorty, Dalit Strauss-Ayali, Gil Hakim, Elyse Seltzer, Mark Schoenberg, and Seth P. Lerner   For users listening from their desktop device, please click on the link below to access clickable show notes.

    26 min

  2. 11/26/2024

    Bringing Real World Data to the Clinic with Dr. Yair Lotan

    In this episode of The UroGist, host Dr. Mike Louie of UroGen sits down with guest Dr. Yair Lotan, Chief of Urologic Oncology at UT Southwestern Medical Center and Medical Director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System for an in-depth look at data derived from real-world patient experiences, insights into the latest real-world evidence and how this information helps shape the future of urologic oncology. Documents to link in episode description:  JELMYTO Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration  JELMYTO Important Safety Information The OLYMPUS Study  JELMYTO Instructions for Administration  Antegrade Administration of JELMYTO  uTRACT Jelmyto Registry – NIH National Cancer Institute  uTRACT Jelmyto Registry – ClinicalTrials.gov  Pharmaceutical Medicine – Amit Dang The Journal of Urology – Surena F. Matin, Phillip M. Pierorazio, Nir Kleinmann, John L. Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott G. Hubosky, Marcelino Rivera, Michael O’Donnell, Marcus Quek, Jay D. Raman, John J. Knoedler, Douglas Scherr, Christopher Weight, Alon Weizer, Michael Woods, Hristos Kaimakliotis, Angela B. Smith, Jennifer Linehan, Jonathan Coleman, Mitchell R. Humphreys, Raymond Pak, David Lifshitz, Michael Verni, Ifat Klein, Marina Konorty, Dalit Strauss-Ayali, Gil Hakim, Elyse Seltzer, Mark Schoenberg, and Seth P. Lerner The Journal of Urology – Solomon L. Woldu, Brett Johnson, Katie S. Murray, Hiroko Miyagi, Wade Sexton, Isamu Tachibana, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Jennifer Linehan, Alan Nieder, Marc Bjurlin, Daniel Heidenberg, Mitchell Humphreys, Saum Ghodoussipour, Marcus L. Quek, Michael O'Donnell, Brian Eisner, Surena Matin, Adam S. Feldman, and Yair Lotan Urologic Oncology  –  Solomon L Woldu, Craig Labbate, Katie S Murray, Kyle Rose, Wade Sexton, Isamu Tachibana, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Jennifer Linehan, Alan Nieder, Marc A Bjurlin, Mitchell Humphreys, Saum Ghodoussipour, Marcus L Quek, Michael O'Donnell, Brian H Eisner, Adam S Feldman, Surena F Matin, Yair Lotan Urologic Oncology – Joseph M Jacob, Solomon L Woldu, Jennifer Linehan, Craig Labbate, Kyle M Rose, Wade J Sexton, Isamu Tachibana, Hristos Kaimakliotis, Alan Nieder, Marc A Bjurlin, Mitchell Humphreys, Saum B Ghodoussipour, Marcus L Quek, Brett Johnson, Michael O'Donnell, Brian H Eisner, Adam S Feldman, Katie S Murray, Surena F Matin, Yair Lotan, Rian J Dickstein European Urology Focus – Jennifer Linehan, Josh Gottlieb, Solomon L Woldu, Craig Labbate, Kyle Rose, Wade Sexton, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Alan Nieder, Marc Bjurlin, Mitchell Humphreys, Saum Ghodoussipor, Marcus Quek, Michael O'Donnell, Brian H Eisner, Adam S Feldman, Surena F Matin, Yair Lotan, Katie S Murray The Journal of Urology – Adam S. Feldman, Solomon L. Woldu, Brett Johnson, Katie S. Murray, Hiroko Miyagi, Wade Sexton, Isamu Tachibana, Hristos Kaimaklotis, Joseph Jacob, Rian Dickstein, Jennifer Linehan, Alan Nieder, Marc Bjurlin, Daniel Heidenberg, Mitchell Humphreys, Saum Ghodoussipour, Marcus L. Quek, Michael O’Donnell, Brian Eisner, Yair Lotan, and Surena Matin For users listening from their desktop device, please click on the link below to access clickable show notes.

    50 min

  3. 10/23/2024

    Antegrade Administration with Dr. Jennifer Linehan

    In this episode of The UroGist, host Dr. Mike Louie of UroGen sits down with guest Dr. Jennifer Linehan, an Associate Professor of Urologic Oncology and Section Head of Urology Translational Research at the St. John's Cancer Institute in Santa Monica, CA to discuss the nuances of antegrade administration of an innovative treatment for low-grade upper tract urothelial cancer.   While discussing the OLYMPUS study, the episode refers to 84% durability [1] for 12 months for patients with low-grade upper tract urothelial cancer, which was found in interim data. The final durability of response data from the OLYMPUS trial for all 41 patients was 82% at 12 months. [2]   ·        JELMYTO Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration ·        The OLYMPUS Study ·        JELMYTO Instructions for Administration ·        Antegrade Administration of JELMYTO ·        uTRACT Jelmyto Registry – NIH National Cancer Institute ·        uTRACT Jelmyto Registry – ClinicalTrials.gov ·        Journal of Urologic Oncology – Joseph M Jacob, Solomon L Woldu, Jennifer Linehan, Craig Labbate, Kyle M Rose, Wade J Sexton, Isamu Tachibana, Hristos Kaimakliotis, Alan Nieder, Marc A Bjurlin, Mitchell Humphreys, Saum B Ghodoussipour, Marcus Quek, Michael O’Donnell, Brian H Eisner, Adam S Feldman, Surena F Martin, Yair Lotan, Katie S Murray ·        European Urology Focus – Jennifer Linehan, Josh Gottlieb, Solomon L Woldu, Craig Labbate, Kyle Rose, Wade Sexton, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Alan Nieder, Marc Bjurlin, Mitchell Humphreys, Saum Ghodoussipor, Marcus Quek, Michael O’Donnell, Brian H Eisner, Adam S Feldman, Surena F Matin, Yair Lotan, Katie S Murray [1] Lerner, Seth. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): a prospective single-arm phase 3 trial. The Lancet Oncology, 2020 [2] Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr;207(4):779-788. doi: 10.1097/JU.0000000000002350. Epub 2021 Dec 17. PMID: 34915741.

    36 min

  4. 09/23/2024

    Treatment Paradigm for Low-Grade Upper Tract Urothelial Cancer with Dr. Katie Murray

    In this inaugural episode of The UroGist, host Dr. Mike Louie of UroGen Pharma welcomes guest Dr. Katie Murray, Professor at NYU Langone Health as well as the Chief of Urology Service at Bellevue Hospital Center, for an informative chat about personalized treatment, management, and subsequent challenges for low-grade upper tract urothelial cancer (LG-UTUC) patients.

    33 min
  • 4 Episodes

Ratings & Reviews

5
out of 5
5 Ratings

About

The UroGist is a podcast series from UroGen Pharma, that takes an informative and engaging look at the latest in urologic oncology through enlightening and interesting conversations with leading urologists and other stakeholders. Hosted by Dr. Michael Louie, the SVP of Medical Affairs and Clinical Development at UroGen. The UroGist seeks to provide a more contextualized understanding of advances in the field that are reshaping the treatment landscape for urologic cancers.

Information

  • Creator
    UroGen® Pharma
  • Years Active
    2024 - 2025
  • Episodes
    4
  • Rating
    Clean
  • Show Website
    The UroGist